Manoj Murlidharan Vayalar, Associate Vice President-Derivatives, IIFL is of the view that one can bet on Dabur India, Ranbaxy Laboratories.

Ranbaxy, Glenmark good opportunities on long side: Kulkarni

Ranbaxy Laboratories and Glenmark Pharma may give opportunities on the long side,says Shardul Kulkarni of Angel Broking

Pharma stocks a defensive play, says Bhat

One can buy defensive stocks like pharma says Dilip Bhat, Joint MD, Prabhudas Lilladher.

Super Six stocks you can bet on April 30

On CNBC-TV18's show Super Six, market gurus Parag Doctor, Vishal B Malkan and Rajesh Jain, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Super Six: Top chart picks for April 26

On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Arunesh Madan of Augment Investment and Shardul Kulkarni, Angel Broking, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Buy Ranbaxy, says Jitendra Panda

Buy Ranbaxy, says Jitendra Panda, Future Capital.

Ranbaxy can test Rs 570-575: Salil Sharma

Ranbaxy Laboratories can test Rs 570-575, says Salil Sharma, Technical Analyst, Kapur Sharma & Co.

Super Six intraday picks for the day

On CNBC-TV18's show Super Six, market gurus Parag Doctor of Keynote Capitals, Vishal B Malkan, CMT, www.malkansview.com and Nooresh Merani of AMSEC Research, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Ranbaxy Laboratories can touch Rs 521: IIFL

Manoj Murlidharan of IIFL feels that Ranbaxy Laboratories can touch Rs 521.

Buy Ranbaxy around Rs 495-500: Salil Sharma

Buy Ranbaxy around Rs 495-500, says Salil Sharma, Technical Analyst, Kapur Sharma & Co.

Bull's Eye: Buy DCB, Shree Renuka, Gitanjali Gems

Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Ranbaxy, Apollo Tyres top picks: Sukhani

Ranbaxy and Apollo Tyres are the top picks, says Sudarshan Sukhani, s2analytics.com.

Ranbaxy can touch Rs 520-530: Sukhani

Ranbaxy can touch Rs 520-530, says Sudarshan Sukhani of s2analytics.com.

Ranbaxy can test Rs 520-525: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com feels that Ranbaxy can test Rs 520-525.

Book some profits in Ranbaxy near Rs 500: LKP

Book some profits in Ranbaxy Laboratories near Rs 500, says Kunal Bothra, LKP.

Buy Ranbaxy on dips, says Sukhani

One can buy Ranbaxy on dips, says Sudarshan Sukhani of s2analytics.com.

Book profits Ranbaxy Laboratories: Kulkarni

One can book profits Ranbaxy Laboratories, says Shardul Kulkarni, Sr Technical Analyst, Angel Broking.

Buy Ranbaxy, says Sukhani

Buy Ranbaxy, says Sudarshan Sukhani of s2analytics.com.

Buying opportunity seen in Ranbaxy Labs: Sukhani

Buying opportunity is seen in Ranbaxy Labs, says Sudarshan Sukhani, s2analytics.com.

Enter Ranbaxy at Rs 452-453: LKP

Enter Ranbaxy at Rs 452-453, says Kunal Bothra, Sr Technical Analyst, LKP.

Bull's Eye: Buy TCS, Shree Renuka, Century Textiles, IVRCL

CNBC-TV18 brings you a brand new week of Bull's Eye. It's the popular game show where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Buy Ranbaxy Labs at current level: Sukhani

Buy Ranbaxy Labs at current level, says Sudarshan Sukhani, www.s2analytics.com.

Ranbaxy can test Rs 460-465: Shardul Kulkarni

Ranbaxy can test Rs 460-465, says Shardul Kulkarni, Sr Technical Analyst, Angel Broking.

Ranbaxy has target of Rs 440: Salil Sharma

Ranbaxy has target of Rs 440, says Salil Sharma, Technical Analyst, Kapur Sharma & Co.

Short Ranbaxy, says Sukhani

Short Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com.